Cationic Lipid Nanoparticles for Serum-Compatible Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid-based delivery systems for nucleic acids are inhibited by serum components, limiting their effectiveness both in vitro and in vivo, necessitating the development of lipids that function effectively in the presence of serum to enhance transfection levels for therapeutic applications.
Innovation Solution
Development of novel cationic lipids, such as those represented by Formulas I-XVI, which form lipid aggregates, carriers, or nanoparticles capable of delivering nucleic acids to cells without the need for additional helper lipids, and can be formulated into liposomes with defined particle sizes and compositions that include nucleic acids like DNA or RNA, enabling efficient transfection even in the presence of serum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid-based delivery systems are used, then transfection can be achieved under low-serum or serum-free conditions, but serum components inhibit the activity of the lipids, limiting their use in the presence of serum
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing specific molecular features (such as modified headgroups, acyl chains, or backbone structures) that change the physical-chemical parameters of the lipid molecules. These structural modifications enable the lipids to maintain their transfection activity and stability in the presence of serum components, thereby resolving the contradiction between transfection reliability and adaptability to serum-containing environments
2Reliability
If higher levels of transfection are achieved, then therapeutic effect is enhanced, but larger amounts of material are required, increasing potential toxicities and costs
Solution Approach 1:
By optimizing the molecular structure of the cationic lipids and adjusting formulation parameters (such as lipid-to-nucleic acid ratio, particle size, or composition ratios), the patent achieves higher transfection efficiency per unit of lipid material. This reduces the total quantity of lipid required to achieve therapeutic transfection levels, thereby decreasing potential toxicities and costs while maintaining or enhancing therapeutic effect
Data Source
AI summary
The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.